Mar 27 |
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
|
Feb 29 |
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript
|
Feb 29 |
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript
|
Feb 29 |
Atea Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
|
Feb 28 |
Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results
|
Feb 28 |
Atea Pharmaceuticals GAAP EPS of -$0.47 beats by $0.03
|
Feb 28 |
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Feb 21 |
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
|
Jan 10 |
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
|
Jan 9 |
Atea gains after mid-stage data for lead asset in Hepatitis C
|